Loading…
← CockpitCompetitor Analysis › GLAND.NS Gland PharmaOpen in the cockpit ↗

Gland PharmaGLAND.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures complex generic injectable drugs for hospitals and pharma companies worldwide, majority-owned by China's Fosun Pharma.

≈ India's Fresenius Kabi/Hikma of injectablesMomentum leader 88
Mkt cap
$5.71B
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$15.4M
20-day average traded
Fwd P/E
39.3×
forward earnings
ROIC−WACC
+5.3 pp
WACC 9.4%
Hurdle
+7 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · INR₹3,230
1D-0.6%
1W-1.0%
1M+7.0%
3M+13.0%
6M+43.5%
YTD+87.6%
1Y+75.8%
ATR %3.3%
Beta0.58
52w lowhigh5.8% off high

What Gland Pharma does

Manufactures complex generic injectable drugs for hospitals and pharma companies worldwide, majority-owned by China's Fosun Pharma.

Makes sterile injectable drugs both for partner companies that sell them under their own labels and under its own filings, and most sales go to regulated markets, with the United States the largest. It widened its contract-manufacturing side by buying Cenexi, a French contract manufacturer.

In one line: India's Fresenius Kabi/Hikma of injectables.

Products and services

  • Generic injectables
  • Contract manufacturing (CDMO)
  • Complex/biosimilar injectables

Customers

  • Global pharma partners
  • Hospitals/distributors (US, Europe, emerging marke

Where it sits in the supply chain

  • API/formulation R&D
  • Sterile injectable manufacturing
  • Global regulatory filings & sales

What could go right

  • US injectable market share gains
  • CDMO partnership growth

What could go wrong

  • US FDA inspection/compliance risk
  • Injectable price erosion

Moat: narrow (regulatory licence, process know-how). US FDA-approved sterile injectable manufacturing facilities are costly and slow for rivals to replicate.

Headquarters: Hyderabad, India · Founded: 1978 · Employees: 4,332

Named competitors

Gland Pharma at a glance

Size Gland Pharma (GLAND.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.71B, the 197th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,230 on 18 Nov 2026.

Performance Over six months the shares gained 43.5%, against -8.4% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 21.9% over the last twelve months (peer median +11.3%); the operating margin is 20.9% (peer median 20.3%).

Valuation It trades at 39.3× forward earnings against a peer median of 22.6× (2nd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.3 points above its cost of capital (9.4% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026GLAND.NS 145Peer median 92
Six months, rebased to 100: Gland Pharma against the median of its 20 peers (local-currency closes).

Gland Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹70.7B₹64.0B₹55.9B₹56.4B₹36.1B
Revenue growth—+15%-1%+56%—
Gross profit₹22.5B₹16.3B₹12.6B₹13.8B₹11.0B
EBITDA₹19.2B₹16.6B₹12.8B₹13.4B₹10.3B
Net income₹12.4B₹10.3B₹6.99B₹7.72B₹7.81B
Free cash flown/a₹7.41B₹6.56B₹7.18B₹2.97B
Capital expendituren/a₹4.94B₹3.94B₹3.98B₹2.23B
Total debt₹2.51B₹2.84B₹3.14B₹3.72B₹44.5M

Quarterly statements and history in the cockpit →

Gland Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-25%0%+25%+50%ABBOTINDIA603087LGNDSUPNMIRM99954506688578BIOCONLQDABLTE326030PTCT0126Z0ORKAGLAND.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Gland Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×60×ABBOTINDIA603087LGNDSUPN99954506688578BIOCONLQDA326030APTX600085GLAND.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gland Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%ABBOTINDIALGNDSUPN688578LQDA326030GLAND.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Gland Pharma is the large dot.

Gland Pharma competitors and peer comparison

Head to head with its named competitors (GLAND.NS vs HIK.L vs SUNPHARMA.NS vs PPLPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Gland Pharma GLAND.NS$5.71B+44%+22%21%39.3×20.2%
Hikma Pharmaceuticals HIK.L$4.58B+15%+2%20%9.8×2.0%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a

How Gland Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gland Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureGLAND.NSPeer medianRank in peer set
1-month return+7.0%+1.2%7th highest of 21
6-month return+43.5%-8.4%2nd highest of 20
Distance from 52-week high-5.8%-25.4%2nd highest of 21
Revenue growth (TTM)+21.9%+11.3%6th highest of 17
Operating margin20.9%20.3%9th highest of 18
Forward P/E39.3×22.6×2nd most expensive of 17
Growth the price implies (Req g, 7 yrs)20.2%1.7%2nd most demanding of 14
Growth delivered (Del g)+13.3%+13.9%7th lowest of 14
Hurdle (Req g minus delivered)+6.8 pp-16.1 pp2nd most demanding of 14
ROIC minus cost of capital+5.3 pp+2.1 pp6th highest of 17
EV / EBITDA26.1×16.8×2nd most expensive of 11
Net debt / EBITDA-1.7×0.1×2nd least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%

Questions

Who are Gland Pharma's main competitors?
Named competitors: Hikma Pharmaceuticals (HIK.L), Fresenius Kabi (private or unlisted), Sun Pharma (SUNPHARMA.NS), Piramal Pharma (PPLPHARMA.NS). The cockpit's measured peer set (industry) also includes Abbott India (ABBOTINDIA.NS), Gan & Lee Pharmaceuticals (603087.SS), Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN), Mirum Pharmaceuticals (MIRM), RemeGen (9995.HK).
Is Gland Pharma expensive compared with its peers?
On forward p/e it trades at 39.3× against a peer median of 22.6×, 2nd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Gland Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +43.5% against -8.4% for the median peer; over one year +75.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.